Company intelligence / Profile preview
Sino Biopharmaceutical Limited
- Ownership
- Private
- Employees
- ~25000
- Development stage
- Commercial
Overview
Sino Biopharmaceutical Limited is one of China's largest pharmaceutical companies with a focus on oncology, hepatology/liver disease, respiratory system disorders and surgery/analgesia. As of mid–2024 it had over seventy innovative products in development—46 oncology drugs alone—and dozens of generics. Its lead program Lanifibranor became the first oral MASH drug to enter Phase III trials in China. The group continues to expand globally through innovation-driven R&D and strategic acquisitions.[5][2]
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularRheumatologyOtherOncologyInfectious Diseases
- Modalities
- Small molecules[1][5]Monoclonal antibodies (mAbs)[1]Bispecific antibodies[1]mRNA delivery systems[1]Soft mist inhalation therapies[1]
- Industry
- Pharma
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Sino Biopharmaceutical Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sino Biopharmaceutical Limited.